BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas

Journal of Clinical Investigation

Volumn 118, Issue 5, 2008, Pages 1739-1749

  Pfister, Stefan ^a,b   Janzarik, Wibke G ^c   Remke, Marc ^a   Ernst, Aurélie ^a   Werft, Wiebke ^a   Becker, Natalia ^a   Toedt, Grischa ^a   Wittmann, Andrea ^a   Kratz, Christian ^d   Olbrich, Heike ^c   Ahmadi, Rezvan ^b   Thieme, Barbara ^e   Joos, Stefan ^a   Radlwimmer, Bernhard ^a   Kulozik, Andreas ^b   Pietsch, Torsten ^f   Herold Mende, Christel ^b   Gnekow, Astrid ^e   Reifenberger, Guido ^g   Korshunov, Andrey ^a,h   Scheurlen, Wolfram ⁱ   Omran, Heymut ^c   Lichter, Peter ^a   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e Hospital for Children and Adolescents   (Germany)

^f UNIVERSITY OF BONN   (Germany)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

ⁱ Nuremberg Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; B RAF KINASE; CYCLIN D1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; SHORT HAIRPIN RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER CELL; CANCER GRADING; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CHILD; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ENZYME ACTIVATION; FEMALE; GENE DUPLICATION; GENE EXPRESSION; GENE MUTATION; GENE NUMBER; GENE SILENCING; GENETIC TRANSDUCTION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LENTIVIRINAE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; TUMOR GROWTH;

ASTROCYTOMA; BRAIN NEOPLASMS; CELL CYCLE; CHILD; CHROMOSOME ABERRATIONS; CYCLINS; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; GENE DUPLICATION; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICROARRAY ANALYSIS; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NUCLEIC ACID HYBRIDIZATION; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 43049124130     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33656     Document Type: Article

References (56)

1. Ohgaki, H., and Kleihues, P. 2005. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 64:479-489.
2. Broniscer, A., et al. 2007. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J. Clin. Oncol. 25:682-689.
3. Watanabe, K., et al. 1997. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin. Cancer Res. 3:523-530.
4. Orr, L., et al. 2002. Cytogenetics in pediatric low-grade astrocytomas. Med. Pediatr. Oncol. 38:173-177.
5. Cheng, Y., et al. 2000. Pilocytic astrocytomas do not show most of the genetic changes commonly seen in diffuse astrocytomas. Histopathology. 37:437-444.
6. Sanoudou, D., Tingby, O., Ferguson-Smith, M., Collins, V., and Coleman, N. 2000. Analysis of pilocytic astrocytoma by comparative genomic hybridization. Br. J. Cancer. 82:1218-1222.
7. Jenkins, R.B., et al. 1989. A cytogenetic study of 53 human gliomas. Cancer Genet. Cytogenet. 39:253-279.
8. Bigner, S.H., McLendon, R.E., Fuchs, M., McKeever, P.E., and Friedman, H.S. 1997. Chromosomal characteristics of childhood brain tumors. Cancer Genet. Cytogenet. 97:125-134.
9. Zattara-Cannoni, H., et al. 1998. Are juvenile pilocytic astrocytomas benign tumors? A cytogenetic study in 24 cases. Cancer Genet. Cytogenet. 104:157-160.
10. Jones, D., et al. 2006. Genomic analysis of pilocytic astrocytomas at 0.97 Mb resolution shows an increasing tendency toward chromosomal copy number change with age. J. Neuropathol. Exp. Neurol. 65:1049-1058.
11. Listernick, R., Ferner, R., Liu, G., and Gutmann, D. 2007. Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations. Ann. Neurol. 61:189-198.
12. Yunoue, S., et al. 2003. Neurofibromatosis type I tumor suppressor neurofibromin regulates neuronal differentiation via its GTPase-activating protein function toward Ras. J. Biol. Chem. 278:26958-26969.
13. Razzaque, M.A., et al. 2007. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat. Genet. 39:1013-1017.
14. Pandit, B., et al. 2007. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat. Genet. 39:1007-1012.
15. Niihori, T., et al. 2006. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat. Genet. 38:294-296.
16. Rodriguez-Viciana, P., et al. 2006. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science. 311:1287-1290.
17. Bentires-Alj, M., Kontaridis, M.I., and Neel, B.G. 2006. Stops along the RAS pathway in human genetic disease. Nat. Med. 12:283-285.
18. Kratz, C., Niemeyer, C., and Zenker, M. 2007. An unexpected new role of mutant Ras: perturbation of human embryonic development. J. Mol. Med. 85:227-235.
19. Bos, J.L., et al. 1987. Prevalence of ras gene mutations in human colorectal cancers. Nature. 327:293-297.
20. Bentires-Alj, M., et al. 2004. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 64:8816-8820.
21. Davies, H., et al. 2002. Mutations of the BRAF gene in human cancer. Nature. 417:949-954.
22. Sharma, M., Zehnbauer, B., Watson, M., and Gutmann, D. 2005. RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology. 65:1335-1336.
23. Janzarik, W., et al. 2007. Further evidence for a somatic KRAS Mutation in a low-grade Astrocytoma. Neuropediatrics. 38:1-3.
24. Sharma, M.K., et al. 2007. Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res. 67:890-900.
25. Rorive, S., et al. 2006. Exploring the distinctive biological characteristics of pilocytic and low-grade diffuse astrocytomas using microarray gene expression profiles. J. Neuropathol. Exp. Neurol. 65:794-807.
26. Solinas-Toldo, S., et al. 1997. Matrix-based comparative genomic hybridization: Biochips to screen for genomic imbalances. Genes Chromosomes Cancer. 20:399-407.
27. Weber, R.G., et al. 2006. Frequent loss of chromosome 9, homozygous CDKN2A//p14ARF// CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas. Oncogene. 26:1088-1097.
28. Hoischen, A., et al. 2008. Comprehensive characterization of genomic aberrations in gangliogliomas by CGH, array-based CGH and interphase FISH. Brain Pathol. In press.
29. Rosenberg, D.W., et al. 2007. Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res. 67:3551-3554.
30. Dessars, B., et al. 2007. Chromosomal translocations as a mechanism of BRAF activation in two cases of large congenital melanocytic nevi. J. Invest. Dermatol. 127:1468-1470.
31. Rajagopalan, H., et al. 2002. Tumorigenesis: RAF/ RAS oncogenes and mismatch-repair status. Nature. 418:934.
32. Brose, M.S., et al. 2002. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62:6997-7000.
33. Xu, X., Quiros, R.M., Gattuso, P., Ain, K.B., and Prinz, R.A. 2003. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 63:4561-4567.
34. Kimura, E.T., et al. 2003. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63:1454-1457.
35. Ciampi, R., et al. 2005. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J. Clin. Invest. 115:94-101.
36. Knobbe, C.B., Reifenberger, J., and Reifenberger, G. 2004. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathologica. 108:467-470.
37. Basto, D., et al. 2005. Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathologica. 109:207-210.
38. Jeuken, J., et al. 2007. RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathologica. 114:121-133.
39. Wimmer, K., et al. 2002. Mutational and expression analysis of the NF1 gene argues against a role as tumor suppressor in sporadic pilocytic astrocytomas. J. Neuropathol. Exp. Neurol. 61:896-902.
40. Wessels, P., et al. 2002. Gain of chromosome 7, as detected by in situ hybridization, strongly correlates with shorter survival in astrocytoma grade 2. Genes Chromosomes Cancer. 33:279-284.
41. Hirose, Y., et al. 2003. Grade II astrocytomas are subgrouped by chromosome aberrations. Cancer Genet. Cytogenet. 142:1-7.
42. Wright, J.H., et al. 1999. Mitogen-activated protein kinase kinase activity is required for the G2/M transition of the cell cycle in mammalian fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 96:11335-11340.
43. Roberts, E.C., et al. 2002. Distinct cell cycle timing requirements for extracellular signal-regulated kinase and phosphoinositide 3-kinase signaling pathways in somatic cell mitosis. Mol. Cell. Biol. 22:7226-7241.
44. Hayne, C., Tzivion, G., and Luo, Z. 2000. Raf-1/ MEK/MAPK pathway is necessary for the G2/M transition induced by nocodazole. J. Biol. Chem. 275:31876-31882.
45. Knauf, J.A., et al. 2006. Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints. J. Biol. Chem. 281:3800-3809.
46. Hermanson, M., et al. 1992. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 52:3213-3219.
47. Miller, S.A., Dykes, D.D., and Polesky, H.F. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16:1215.
48. van den Boom, J., et al. 2003. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am. J. Pathol. 163:1033-1043.
49. Mendrzyk, F., et al. 2005. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J. Clin. Oncol. 23:8853-8862.
50. Zielinski, B., et al. 2005. Detection of chromosomal imbalances in retinoblastoma by matrix-based comparative genomic hybridization. Genes Chromosomes Cancer. 43:294-301.
51. Rocchi, M., Archidiacono, N., Ward, D., and Baldini, A. 1991. A human chromosome 9-specific alphoid DNA repeat spatially resolvable from satellite 3 DNA by fluorescent in situ hybridization. Genomics. 9:517-523.
52. Bubendorf, L., et al. 1999. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res. 59:803-806.
53. Lichter, P., Cremer, T., Borden, J., Manuelidis, L., and Ward, D. 1988. Delineation of individual human chromosomes in metaphase and interphase cells by in situ suppression hybridization using recombinant DNA libraries. Hum. Genet. 80:224-234.
54. Freier, K., et al. 2003. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res. 63:1179-1182.
55. Pfaffl, M.W. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45.
56. Moffat, J., et al. 2006. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 124:1283-1298.